May. 5 at 11:27 AM
$BNTX $BMY
🚨🚨🚨🚨
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb
Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates and antibody-drug conjugate programs
Catalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies
COVID-19 2026/2027 season variant-adapted vaccine development and commercial preparation underway
First quarter 2026 revenues of €118.1 million1, net loss of €531.9 million (adjusted2 net loss of €494.6 million), with diluted loss per share of €2.10 (
$2.463) (adjusted2 diluted loss per share of €1.95 (
$2.283))
Reaffirmed full year 2026 financial guidance and strong financial position continue to de-risk execution with cash, cash equivalents and security investments of €16.8 billion4
Share repurchase program of up to
$1.0 billion over twelve months planned
